Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

SUNNYVALE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended June 30, 2021.

Silk Road Medical Reports Second Quarter 2021 Financial Results

SUNNYVALE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors.

Silk Road Medical Names Dr. Tanisha Carino to Board of Directors

SUNNYVALE, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2021 after market close on Thursday, July 29, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Second Quarter 2021 Financial Results on July 29, 2021

SUNNYVALE, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid disease, including patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR), will be presented at the upcoming Society for Vascular Surgery 2021 Vascular Annual Meeting (VAM), August 18 –21 at the San Diego Convention Center in San Diego, California.

First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting

SUNNYVALE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, recently announced the opening of a new office in Plymouth, Minnesota, to accommodate growing demand for TransCarotid Artery Revascularization (TCAR) and to access the local talent pool of aspiring and experienced med tech professionals.

Silicon Valley-Based Silk Road Medical Announces Expansion to MSP Region

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q1 2021 Results - Earnings Call Transcript

Shares of Silk Road Medical (NASDAQ:SILK) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 3.13% over the past year to ($0.31), which beat the estimate of ($0.39).

Silk Road Medical: Q1 Earnings Insights

SUNNYVALE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended March 31, 2021.

Silk Road Medical Reports First Quarter 2021 Financial Results

SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.

Silk Road Medical to Present at BofA Securities 2021 Virtual Health Care Conference

SUNNYVALE, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2021 after market close on Tuesday, May 4, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report First Quarter 2021 Financial Results on May 4, 2021

SUNNYVALE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of William Hill as General Counsel. The veteran corporate executive joins the company to oversee all risk management and legal matters, reporting directly to President and Chief Executive Officer, Erica Rogers.

Silk Road Medical Appoints William Hill as General Counsel

Silk Road Medical (SILK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Silk Road Medical (SILK)

Bear of the Day: Silk Road Medical (SILK)

Silk Road Medical, Inc's (SILK) CEO Erica Rogers on Q4 2020 Results - Earnings Call Transcript

Silk Road Medical (SILK) delivered earnings and revenue surprises of -63.33% and -0.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q4 Loss, Lags Revenue Estimates

Shares of Silk Road Medical (NASDAQ:SILK) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 70.37% over the past year to ($0.46), which missed the estimate of ($0.28).

Recap: Silk Road Medical Q4 Earnings

Submitted PMA Supplement for ENROUTE Stent in Standard Surgical Risk Patients

Silk Road Medical Reports Fourth Quarter and Full Year 2020 Financial Results

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Silk Road Medical (SILK) Q4 Earnings Expected to Decline

SUNNYVALE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 1, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

Silk Road Medical has delivered resilient operational growth in recent times, even amidst Covid-19. I like the product and the growth, yet it seems that 2020s price action reflects quite some good news.

Silk Road Medical - Growing Along

SUNNYVALE, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

Silk Road Medical to Present at the 39th Annual J.P. Morgan Healthcare Conference

Eargo

Nano-X Imaging

Outset Medical

Transmedics Group Inc

LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road Medical, Inc. (NASDAQ:SILK) as best Health-Tech companies to watch in 2021-2022. The report provides an overview and brief assessment of 5 highly impactful and promising medical hardware technologies to be watched in 2021-2022, and the companies behind their development and commercialization. In the case

Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022

SUNNYVALE, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to the company's Board of Directors. Simultaneously, the company also announced the resignation of current board member, Ruoxi Chen. Both of these changes are effective immediately.

Silk Road Medical Announces Changes to Board of Directors

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q3 2020 Results - Earnings Call Transcript

Shares of Silk Road Medical (NASDAQ:SILK) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 19.23% over the past year to ($0.31), which missed the estimate of ($0.28).

News for Silk Road Medical Inc Stock (SILK)